NOTE
21 – Loss Per Share
The
following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of
dilutive potential common stock for the years ended February 28, 2026 and February 28, 2025:
Schedule of Earnings Per Share, Basic and Diluted
| | |
2026 | | |
2025 | |
| | |
Year Ended February | |
| | |
2026 | | |
2025 | |
| Loss from continuing operations | |
$ | (15,911,934 | ) | |
$ | (10,128,428 | ) |
| Preferred dividends | |
| (335,662 | ) | |
| (78,600 | ) |
| Loss from continuing operations applicable to common stockholders | |
| (16,247,596 | ) | |
| (10,207,028 | ) |
| Gain (loss) from discontinued operations applicable to common stockholders | |
| - | | |
| 8,344 | |
| Net loss applicable to common stockholders | |
$ | (16,247,596 | ) | |
$ | (10,198,684 | ) |
| | |
| | | |
| | |
| Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) | |
| 8,930,520 | | |
| 4,566,787 | |
Dilutive
loss per share was not presented as the Company’s outstanding common and preferred warrants, stock options and preferred stock
common equivalent shares for the periods presented would have had an anti-dilutive effect. At February 28, 2026, the Company had outstanding
warrants to purchase 4,758,581 shares of common stock; stock options exercisable for 914,825 shares of common stock; 100,000 shares of
Series A Preferred, convertible into 100,000 shares of common stock; and 316 shares of Series E Preferred, which could be converted into
3,570 shares of common stock. At February 28, 2025, the Company had 6,201,890 outstanding potentially dilutive securities.
|